# EDGAR Filing Document

**Accession Number:** 0000832489
**File Stem:** 0001437749-26-020984
**Filing Date:** 2026-6
**Character Count:** 8764
**Document Hash:** a0a521efa0a30576113e134f41a20e7d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-020984.hdr.sgml**: 20260617

**ACCESSION NUMBER**: 0001437749-26-020984

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260617

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260617

**DATE AS OF CHANGE**: 20260617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GeoVax Labs, Inc.
- **CENTRAL INDEX KEY:** 0000832489
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870455038
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39563
- **FILM NUMBER:** 261099010

**BUSINESS ADDRESS:**
- **STREET 1:** 1955 LAKE PARK DRIVE
- **STREET 2:** SUITE 300
- **CITY:** SMYRNA
- **STATE:** GA
- **BUSINESS PHONE:** 678-384-7220

**MAIL ADDRESS:**
- **STREET 1:** 1955 LAKE PARK DRIVE
- **STREET 2:** SUITE 300
- **CITY:** SMYRNA
- **STATE:** GA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Geovax Labs, Inc.
- **DATE OF NAME CHANGE:** 20061002

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DAUPHIN TECHNOLOGY INC
- **DATE OF NAME CHANGE:** 19940826

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SUCCESSO INC
- **DATE OF NAME CHANGE:** 19910410

?xml version='1.0' encoding='ASCII'? govx20260617_8k.htm

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 17, 2026**

------

**GEOVAX LABS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39563** | **87-0455038** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(Commission File No.)** | **(IRS Employee Identification No.)** |

---

**1955 Lake Park Drive, Suite 300**

**Smyrna, Georgia 30080**

**(Address of principal executive offices) (Zip code)**

**(678) 384-7220**

**(Registrant**'**s telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading<br>Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | GOVX | The Nasdaq Capital Market |

---

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Submission of Matters to a Vote of Security Holders.**

The Company held its annual meeting of stockholders on June 17, 2026. The Company received proxies totaling 1,288,684 of its 2,892,570 issued and outstanding shares of common stock as of the record date of April 20, 2026. The stockholders voted on the following proposals and the results of the voting are presented below.

**Election of Directors**

Our stockholders voted to elect the slate of directors consisting of seven members to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified. There were a total of 810,066 broker non-votes on this item.

---

| | | |
|:---|:---|:---|
| **<u>Nominee</u>** | &nbsp;&nbsp;**<u>For</u>** | &nbsp;&nbsp;**<u>Withheld</u>** |
| Randal D. Chase | &nbsp;&nbsp;420305 | &nbsp;&nbsp;58313 |
| David A. Dodd | &nbsp;&nbsp;418963 | &nbsp;&nbsp;59655 |
| Dean G. Kollintzas | &nbsp;&nbsp;420198 | &nbsp;&nbsp;58420 |
| Nicole Lemerond | &nbsp;&nbsp;417920 | &nbsp;&nbsp;61426 |
| Robert T. McNally | &nbsp;&nbsp;419481 | &nbsp;&nbsp;59137 |
| Jayne Morgan | &nbsp;&nbsp;420422 | &nbsp;&nbsp;58196 |
| John N. Spencer, Jr. | &nbsp;&nbsp;420434 | &nbsp;&nbsp;58184 |

---

**Approval of the February 2026 Warrant Exercise Proposal**

Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 865,804 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the private placement offering which occurred on February 17, 2026. There were a total of 810,066 broker non-votes on this item.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**<u>For</u>** | &nbsp;&nbsp;**<u>Against</u>** | &nbsp;&nbsp;**<u>Abstain</u>** |
| &nbsp;&nbsp;395,198 | &nbsp;&nbsp;65,103 | &nbsp;&nbsp;18,317 |

---

**Approval of the March 2026 Warrant Exercise Proposal**

Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 1,269,316 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the warrant exercise inducement which occurred on March 31, 2026. There were a total of 810,066 broker non-votes on this item.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**<u>For</u>** | &nbsp;&nbsp;**<u>Against</u>** | &nbsp;&nbsp;**<u>Abstain</u>** |
| &nbsp;&nbsp;395,365 | &nbsp;&nbsp;66,838 | &nbsp;&nbsp;16,415 |

---

**Approval of the May 2026 Warrant Exercise Proposal**

Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 1,702,986 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the warrant exercise inducement which occurred on May 7, 2026. There were a total of 810,066 broker non-votes on this item.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**<u>For</u>** | &nbsp;&nbsp;**<u>Against</u>** | &nbsp;&nbsp;**<u>Abstain</u>** |
| &nbsp;&nbsp;375,831 | &nbsp;&nbsp;35,336 | &nbsp;&nbsp;67,451 |

---

**Ratification of Independent Auditor**

Our stockholders approved the ratification of Wipfli LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. There were no broker non-votes on this item.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**<u>For</u>** | &nbsp;&nbsp;**<u>Against</u>** | &nbsp;&nbsp;**<u>Abstain</u>** |
| &nbsp;&nbsp;1,185,525 | &nbsp;&nbsp;37,409 | &nbsp;&nbsp;65,750 |

---

------

**Advisory Vote on the Compensation of our Named Executive Officers**

Our stockholders approved, on an advisory basis, the compensation of our Named Executive Officers (as defined in the Proxy Statement). There were a total of 810,066 broker non-votes on this item.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**<u>For</u>** | &nbsp;&nbsp;**<u>Against</u>** | &nbsp;&nbsp;**<u>Abstain</u>** |
| &nbsp;&nbsp;385,843 | &nbsp;&nbsp;65,826 | &nbsp;&nbsp;26,949 |

---

**Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers**

Our stockholders approved, on an advisory basis, the frequency of future advisory votes on the compensation of our Named Executive Officers (as defined in the Proxy Statement). The determination was to hold such advisory votes on a three-year cycle.

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**<u>1 Year</u>** | &nbsp;&nbsp;**<u>2 Years</u>** | &nbsp;&nbsp;**<u>3 Years</u>** | &nbsp;&nbsp;**<u>Abstain</u>** |
| &nbsp;&nbsp;339,064 | &nbsp;&nbsp;24,463 | &nbsp;&nbsp;97,058 | &nbsp;&nbsp;18,033 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 17, 2026

---

| | |
|:---|:---|
| GEOVAX LABS, INC. | GEOVAX LABS, INC. |
| By: | */*s/ Mark W. Reynolds |
|  | Mark W. Reynolds |
|  | Chief Financial Officer |

---